ProCE Banner Activity

Novel Frontline Strategies for Advanced HCC

Slideset Download

Download this slideset for expert perspectives on novel systemic therapy regimens for patients with advanced hepatocellular carcinoma, including PD-1/PD-L1 inhibitor plus CTLA-4 inhibitor or multikinase inhibitor combinations.

Released: February 04, 2022

Share

Faculty

Adam Burgoyne

Adam Burgoyne, MD, PhD

Assistant Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
UC San Diego Moores Cancer Center
La Jolla, California

Lipika Goyal

Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

Stacey Stein

Stacey Stein, MD

Assistant Professor of Medicine
Yale University School of Medicine
Section of Medical Oncology
New Haven, Connecticut

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Eisai Inc.

Exelixis

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Adam Burgoyne, MD, PhD

Assistant Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
UC San Diego Moores Cancer Center
La Jolla, California

Adam M. Burgoyne, MD, PhD, has disclosed that he has received consulting fees from Deciphera, Exelixis, and Genentech.

Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

Lipika Goyal, MD, MPhil, has disclosed that she has received consulting fees from Alentis, AstraZeneca, Black Diamond, Exelixis, H3 Biomedicine, Incyte, QED, Servier, Sirtex, and Taiho and research support paid to her institution from Adaptimmune, Bayer, Bristol-Myers Squibb, Eisai, Genentech, Incyte, Leap Therapeutics, Lilly, Loxo Oncology, MacroGenics, Merck, Novartis, NuCana, QED, Relay Therapeutics, Servier, and Taiho.

Stacey Stein, MD

Assistant Professor of Medicine
Yale University School of Medicine
Section of Medical Oncology
New Haven, Connecticut

Stacey M. Stein, MD, has disclosed that she has received consulting fees from AstraZeneca, Eisai, Genentech, Merck, and QED.